Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,066 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Injection Clear all
Completed Phase 1 Interventional Results available

Stem Cell Injection in Cancer Survivors

NCT02509156
View directory record Official record
Conditions
Cardiomyopathy Due to Anthracyclines
Interventions
Allo-MSCs, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 20, 2026, 2:07 AM EDT
Recruiting Early Phase 1 Interventional

CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer

NCT07278986
View directory record Official record
Conditions
Endometrial Cancer, Near Infrared Fluorescence Imaging, CYTALUX (Pafolacianine) Injection, Planned Diagnostic Laparoscopies
Interventions
CYTALUX™ (pafolacianine), 1788 4K Camera System with Advanced Imaging Modality
Drug · Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

NCT03739931
View directory record Official record
Conditions
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Interventions
mRNA-2752, Durvalumab
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
16
States / cities
San Francisco, California • Santa Monica, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

NCT01449682
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Ozurdex
Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 20, 2026, 2:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

NCT07392255
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
CTx001
Genetic
Lead sponsor
Complement Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
Carmel, Indiana • Reno, Nevada • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Not applicable Interventional Results available

Cooled Radiofrequency vs. Hyaluronic Acid to Manage Knee Pain

NCT03381248
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Cooled Radiofrequency, Hyaluronic Acid Injection, Crossover from Hyaluronic Acid Injection to Cooled Radiofrequency
Device · Other
Lead sponsor
Avanos Medical
Other
Eligibility
21 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Coeur d'Alene, Idaho • New Orleans, Louisiana • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

NCT03589885
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Not applicable Interventional

Submucosal Injection EMR vs. Underwater EMR for Colorectal Polyps

NCT01712048
View directory record Official record
Conditions
Colonic Polyps, Rectal Polyps
Interventions
Submucosal Injection EMR, Underwater EMR
Procedure
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 20, 2026, 2:07 AM EDT
Terminated Phase 1 Interventional

Pilot Study of Therapy With Hylan G-F 20 Exercise Capacity

NCT01810848
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Hylan G-F 20, Control
Device · Other
Lead sponsor
OhioHealth
Other
Eligibility
40 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

NCT06627413
View directory record Official record
Conditions
Schizophrenia or Schizoaffective
Interventions
Lumateperone Capsule, Lumateperone LAI
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Los Alamitos, California • Atlanta, Georgia • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014635
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 20, 2026, 2:07 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines

NCT07756580
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, BOTOX
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Glendale, Arizona • Newport Beach, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

NCT02055274
View directory record Official record
Conditions
Parkinson's Disease
Interventions
LY03003, Neupro
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Long Beach, California • Orlando, Florida • Douglasville, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 20, 2026, 2:07 AM EDT
Terminated Phase 2 Interventional Results available

GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

NCT01176513
View directory record Official record
Conditions
Prostate Cancer
Interventions
GE-148 (18F)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.

NCT04256434
View directory record Official record
Conditions
Health
Interventions
Dinalbuphine sebacate, Nalbuphine HCl
Drug
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Phase 1 Interventional

CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)

NCT03086616
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
2 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Phase 2Phase 3 Interventional

EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial

NCT00233038
View directory record Official record
Conditions
Pancreatic Cystadenoma
Interventions
Ethanol injection into a cyst
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Not applicable Interventional Results available

Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis

NCT01830699
View directory record Official record
Conditions
Subacromial Bursitis
Interventions
Rilonacept, Corticosteroid
Drug
Lead sponsor
Keesler Air Force Base Medical Center
Federal
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Keesler Air Force Base, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Pilot Study to Evaluate Skin Swabbing With Chlorhexidine to Prevent Skin And Soft Tissue Infections Among People Who Inject Drugs

NCT06733506
View directory record Official record
Conditions
Opioid Use Disorder, Injection Drug Use, Skin and Soft Tissue Infections (SSTIs)
Interventions
Chlorhexidine gluconate, Isopropyl Alcohol 70% Topical Application Solution, Skin Prep Before Injecting Recreational/Street Drugs
Drug · Behavioral
Lead sponsor
Gabriel John Culbert
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 20, 2026, 2:07 AM EDT
Not yet recruiting Phase 3 Interventional

A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

NCT07733947
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9 % sodium chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Not applicable Interventional

A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

NCT00002292
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
LyphoMed
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rosemont, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 2:07 AM EDT
Completed Not applicable Interventional

Zona Pellucida Bound Sperm vs. Embryologist Selected Sperm for Intracytoplasmic Sperm Injection

NCT05859152
View directory record Official record
Conditions
Infertility
Interventions
Zona Pellucida-Bound Sperm Selection for ICSI, Routine Embryologist Selected Sperm
Other
Lead sponsor
IVI America
Other
Eligibility
18 Years to 41 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 20, 2026, 2:07 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
82
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 20, 2026, 2:07 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride

NCT06820164
View directory record Official record
Conditions
Lipoma
Interventions
Cooled Sodium Chloride Injection, Warmed Sodium Chloride Injection
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 20, 2026, 2:07 AM EDT